In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA markets Novartis' Starlix to treat diabetes

Executive Summary

Merck KGAA will co-promote and co-market Novartis' Starlix (nateglinide) in Europe, and specific African, Southeast Asian, and Latin American countries to treat Type II diabetes. The agreement will remain in place for as long as the drug is under patent.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Co-Promotion
    • Co-Marketing

Related Companies